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ABSTRACT Understanding the mechanism(s) underpinning drug resistance could
lead to novel treatments to reverse the increased tolerance of a pathogen. In this
study, paromomycin (PMM) resistance (PMMr) was induced in three Nepalese clinical
strains of Leishmania donovani with different inherent susceptibilities to antimony
(Sb) drugs by stepwise exposure of promastigotes to PMM. Exposure to PMM re-
sulted in the production of mixed populations of parasites, even though a single
cloned population was used at the start of selection. PMM 50% inhibitory concentra-
tion (IC50) values for PMMr parasites varied between 104 and 481 M at the promas-
tigote stage and 32 and 195 M at the intracellular amastigote stage. PMM resis-
tance was associated with increased resistance to nitric oxide at the amastigote
stage but not the promastigote stage (P 0.05). This effect was most marked in the
Sb-resistant (Sbr) PMMr clone, in which PMM resistance was associated with a signifi-
cant upregulation of glutathione compared to that in its wild type (P 0.05), al-
though there was no change in the regulation of trypanothione (detected in its oxi-
dized form). Interestingly, PMMr strains showed an increase in either the keto acid
derivative of isoleucine (Sb intermediate PMMr) or the 2-hydroxy acids derived from
arginine and tyrosine (Sb susceptible PMMr and Sbr PMMr). These results are consis-
tent with the recent finding that the upregulation of the branched-chain amino acid
aminotransferase and D-lactate dehydrogenase is linked to PMMr. In addition, we
found that PMMr is associated with a significant increase in aneuploidy during PMM
selection in all the strains, which could allow the rapid selection of genetic changes
that confer a survival advantage.
KEYWORDS Leishmania donovani, paromomycin, metabolomics, lipidomics,
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Visceral leishmaniasis (VL), a disease caused by infection with the protozoan para-sites Leishmania donovani and L. infantum (syn., L. chagasi), is fatal if left untreated.
There are 360 million people at risk of infection, and in 2017, the global incidence was
estimated to be between 50,000 and 90,000 new VL cases each year, with most of them
occurring in just six countries (1). Coinfection with HIV is associated with exacerbated
disease and a poorer chemotherapeutic prognosis (2). Disease control is primarily focused
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on vector control and drug treatment of clinical cases, as there is no vaccine to protect
people against infection. There are a limited number of drugs to treat VL, and treatment
failure and/or drug resistance is jeopardizing their efficacy, as already illustrated in the cases
of antimony (Sb) drugs (3, 4) and miltefosine (MIL) (5). With the expectation of new
compounds, alternative drugs, such as amphotericin B (AMB; or its liposomal formulation,
AmBisome), as well as combination therapy are being used as first-line treatment in some
areas where VL is endemic. Paromomycin (PMM) is an aminoglycoside antibiotic that has
been shown to have activity against Leishmania and that is increasingly tested in combi-
nation regimens (6). In Bangladesh, in combination with MIL or AmBisome, PMM showed
efficacy similar to that of AmBisome monotherapy for the treatment of VL (7). A study has
shown that combined sodium stibogluconate (SSG) and PMM treatment in Sudan, Kenya,
Uganda, and Ethiopia was an effective first-line option for VL chemotherapy (8). A retro-
spective study on the treatment of post-kala azar dermal leishmaniasis (PKDL), a compli-
cation of VL, showed that combination therapy with PMM was more effective than
monotherapy with SSG in East Africa (9).
Experimental work showed that the selection of PMM resistance (PMMr) in L. donovani
was rather easy and fast (10, 11). Given the increased usage of PMM in clinical practice, it
is thus important to understand the molecular mechanisms underlying PMM resistance in
Leishmania. The drug is known to downregulate protein synthesis, and it has been shown
to affect multiple protein targets in L. donovani (12). The cytoplasmic target of PMM is the
decoding A site of the small subunit (SSU) of ribosomes, where it increases misreading and
translation inhibition. Steric hindrance caused by a 1408A-to-Gmutation at the gene region
encoding the 18S rRNA helix h44, which forms part of the A site or the rRNA, was thought
to be responsible for the poor binding of PMM to eukaryotic cytosolic ribosomes. Mutations
at positions 1408 and 1491 are known to be important in determining sensitivity to PMM
(13). A study using a high-throughput cosmid sequencing (Cos-Seq) approach identified
genetic changes on 5 chromosomes that conferred PMM resistance in L. infantum. How-
ever, the product of these gene sequences was unknown and Cos-Seq could not identify
loss-of-function targets (14). Previous work showed that the molecular mechanisms of drug
resistance may vary with the genetic background of the parasite (15). In the present study,
we thus selected for PMMr in three L. donovani clinical strains from Nepal with different
susceptibilities to Sb drugs and different genetic backgrounds. The wild-type (WT) strains
were previously phenotyped as Sb sensitive (Sbs), Sb intermediate (Sbi), or Sb resistant (Sbr),
respectively (16). We characterized the effect of PMMr on the metabolomes of the strains
as well as their infectivity and susceptibility to antimicrobial products produced by mac-
rophages. We sequenced the whole genomes of the Sbs and Sbr strains during induction
of PMMr. We show polymorphic molecular changes among the different PMMr strains.
RESULTS
PMM susceptibility (PMMs) upon adaptation of Sbs, Sbi, and Sbr lines to PMM.
The Sbs WT parent strain used here (strain BPK280/0cl4) was previously found to be
intrinsically less susceptible to PMM than the other two L. donovani strains used in this
study (Table 1). However, this strain was submitted to the same PMM resistance
selection protocol to determine if PMM selection resulted in increased PMM resistance,
as studies have shown that drug-resistant parasites can lose their drug resistance if
drug pressure is removed (17). After adaptation of the parasites to grow in 97 M PMM,
promastigotes of the induced Sbs PMMr parent line had a lower 50% inhibitory
concentration (IC50) value than the WT, but cloned lines from this parent had either an
IC50 lower than that for the original WT or an IC50 value similar to that of the original
WT after PMM selection (Table 1; data for one cloned line are shown). This may indicate
that there is an upper limit of the ability of this strain to tolerate PMM exposure and
that selection resulted in the expansion of different subclones from the original WT. At
the amastigote stage, the Sbs PMMr parent and cloned line had a similar or lower
susceptibility to PMM (Table 1). In contrast, selection using PMM resulted in increased
resistance to PMM at both the promastigote and the amastigote stages for the Sbi
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strain (BPK087/0cl11) and Sbr strain (BPK275/0cl18). The PMMr cloned lines from the
PMMr Sbi or PMMr Sbr parent had similar susceptibilities to PMM (Table 1).
Metabolomic profile of PMMr parasites. Metabolites of the three L. donovani
PMMr clones, i.e., Sbs PPMr clone 8, Sbi PMMr clone 8, and Sbr PMMr clone 9, and their
corresponding WTs were extracted on the same day of culture from parasites that grew
at the same rate and analyzed to identify the metabolomic changes associated with
PMM resistance. The same 212 metabolites were putatively identified in all six lines (see
Excel Files 1 and 1a in the supplemental material posted at https://doi.org/10.15129/
88f47c26-ff93-4a7c-8c17-d323aa24052e). Principal-component analysis (PCA) showed
that replicates of each of the L. donovani strains clustered into separate groups (Fig. 1A).
Clear differences were obvious when each WT was compared to its corresponding
PMMr derivative using orthogonal projections to latent structures discriminant analysis
(OPLS-DA) (Fig. 1B to D), indicating that clear metabolic differences occurred on
adaptation to 97 M PMM. Overall, there were more differences in the Sbi PMMr and
Sbr PMMr strains than in the Sbs PMMr strain (see Tables S1 and S2 posted at the
website indicated above). Figure 2 shows a heat map of the relative expression of
the metabolites shown in Table S1, to highlight the effect of the induction of PMMr on
the metabolomic profiles of the parasites. Metabolic changes occurred in a number of
biochemical pathways, i.e., amino acid metabolism, glutathione metabolism, carbohy-
drate metabolism, glycolysis, the tricarboxylic acid (TCA) cycle, and nucleotide metab-
olism. It was possible to relate some changes to specific biochemical pathways within
pairs of strains. For example, Leishmania species produce hydroxy acid derivatives of
aromatic amino acids and arginine (18). This process requires the production of a 2-keto
acid by transamination of the amino acid, followed by reduction of the keto acid to
form the corresponding 2-hydroxy acid (Fig. 3a), and specific products for arginine,
tyrosine, and tryptophan were detected in the metabolic profile (Fig. 3b and c).
Significant differences in arginine metabolites were observed, with a large decrease in
2-oxoarginine levels and a corresponding increase in arginic acid levels being seen for
the Sbr PMMr clone compared to its WT (Fig. 3c). The same trends were found for the
Sbs PMMr clone, although the changes were smaller and generally below the 2-fold
threshold. In contrast, the Sbi PMMr clone had significantly higher levels of the keto acid
derivatives of arginine and tyrosine (2-oxoarginine and hydroxyphenyl pyruvate [HPA],
respectively) but no significant changes in the corresponding 2-hydroxy acids (arginic
acid and hydroxyphenyllactate [HPLA]). The changes in 2-hydroxy acids indicate an
increased amount of 2-hydroxy acid dehydrogenase, although the metabolic enzymes
responsible for this activity have not been identified in Leishmania. This activity could
be important for NAD/NADH recycling to maintain the redox balance within the
promastigote, so the change could be an indirect effect of PMMr. The levels of
tryptophan varied between the strains, but there was no corresponding difference in
the levels of its hydroxy acid derivative, indolelactate. Arginine is involved in a number
TABLE 1 Relative susceptibility (IC50) of different L. donovani strains to PMM
Strain phenotype Isolate
Mean  SD PMM IC50 (M)a
Promastigote Amastigote
Sbs WT 354  4 166  11
PMMr parent 116  29 149  20
PMMr clone 8 305  27 155  26
Sbi WT 56  22 56  18
PMMr parent 455  6* 156  20*
PMMr clone 8 481  84* 195 12*
Sbr WT 65  2 67  1
PMMr parent 455  6* 165  20*
PMMr clone 9 455  6* 165  20*
aThe data show the mean IC50 from a minimum three separate experiments. *, P 0.05 compared to the
corresponding WT.
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of metabolic pathways (Fig. 4) and could affect proline levels. Proline has been shown
to protect against oxidative stress, and its upregulation has been associated with drug
resistance (18). Proline levels were upregulated in the Sbi PMMr clone compared to
those in its WT but not the other two PMMr clones. Therefore, in order to determine if
proline could mediate PMM resistance in the Sbs and Sbi strains, the WT strains and
their corresponding PMMr clones were exposed to PMM at different concentrations in
medium supplemented with proline. Addition of proline to the medium had no
significant effect on parasite growth or the response to PMM treatment, giving further
evidence that proline is not involved in PMMr. Trypanothione, the main intracellular
thiol and reducing agent in trypanosomatids, was detected (in its oxidized form), but
there were no differences observed between WT strains and their PMMr derivatives (Fig.
4). It should be noted that thiols can be oxidized in situ during liquid chromatography-
mass spectrometry (LC-MS), and the levels observed are indicative of the total amount
in the extract rather than their oxidation state in vivo. Other compounds can also
protect against oxidative stress, and in the Sbr PMMr clone, there was a significant
upregulation in the levels of glutathione (P 0.05). However similar metabolic changes
were not present in the other two PMMr clones (Fig. 4). PMMr had little effect on the
glucose metabolism of the parasites, as the levels of the majority of the metabolites in
the TCA cycles were unaffected compared to those in the WT strains (Fig. S1). This could
indicate that PMMr does not require active transport mechanisms that require energy.
Lipidomic profile of PMM-resistant parasites. The regulation of none of the lipids
identified in lipidome studies was significantly altered after PMMr selection for the Sbi
PMMr strain compared to that in its WT (Table S2). In contrast, 7 lipids were significantly
FIG 1 Multivariate analysis of data from LC-MS was performed using the SIMCA program. There are 214
features (metabolite peak intensity values) per sample. Plots show the scores resulting from modeling of
the data matrix: PCA-X analysis of all samples (A), OPLS-DA of Sbs strains (B), OPLS-DA of Sbi strains (C),
and OPLS-DA of Sbr strains (D). Ellipses represent 95% tolerance limits (Hotelling’s T-squared distribution
[T2]) (35).
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downregulated and 1 lipid (sphingenine) was upregulated in the Sbr PMMr strain
compared to their regulation in its WT. Of these 7, 4 lipids were small, unsaturated
phosphatidylethanolamines (PEs; two diacyl PEs, one alky-acyl PE, and one alkenyl-acyl
PE). The other three were a ceramide, a phosphatidylinositol, and a lysophosphatidyle-
thanolamine (Table S2). In the Sbs PMMr strain, there was a significant upregulation of
4 alkyl-acyl phosphatidylinositols. There was also a significant reduction of 4 other lipids
that are not structurally related.
PMMr does not affect infectivity but influences macrophage responses. In
previous studies of MIL-resistant (MILr) parasites derived from the same WT parents, we
found that MILr was associated with a reduction in macrophage infectivity (19).
Therefore, studies were carried out to determine if PMM resistance affected parasite
fitness by assessing their ability to infect macrophages and their susceptibility to the
antimicrobial products produced by macrophages. PMMr was not associated with a
reduction in infectivity for macrophages, as parasite levels were similar in macrophages
infected with WT or PMMr parasites (data not shown). Sbs PMMr parasites had a
significantly greater resistance to gamma interferon (IFN-)- and lipopolysaccharide
(LPS)-induced killing than the WT (P 0.05), but only if cells were treated with the
lower doses of IFN- and LPS (i.e., 50 units IFN- and 50 ng LPS/ml versus 100 units
IFN- and 100 ng LPS/ml; data not shown). The Sbi and Sbr PMMr parasites did not
demonstrate a consistent difference in susceptibility to IFN-- and LPS-induced killing
from their corresponding WT at either dose (data not shown). Treatment with S-nitroso-
N-acetyl-D,L-penicillamine (SNAP), a nitric oxide (NO) inducer, caused a dose-dependent
reduction in parasite survival, and the effect was not related to any difference in NO
production, as similar amounts of nitrite were present in the supernatants of uninfected
and infected macrophages treated with SNAP (data not shown). The Sbs WT and Sbs
PMMr promastigotes had similar tolerances to SNAP-induced parasite killing, whereas
the Sbi PMMr and Sbr PMMr clones were less resistant to NO exposure than their
respective WT strains (Table 2). At the intracellular amastigote stage, all independently
FIG 2 Effect of PMM selection on the metabolic profile of PMMr L. donovani promastigotes compared to
that of the WT. Heat maps of metabolite levels (mean peak intensity) were generated using Metabo-
analyst (v4.0) software. The map shows the mean metabolite levels for the different L. donovani strains
(columns) based on mean peak intensity values from LC-MS (rows). Deep red represents the highest level,
and deep blue represents the lowest level, with white representing equal levels. Each group is identified
by a colored bar at the top of each column and by the name of the strain at the bottom. These data are
representative of those from three separate experiments.
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cloned Sbs promastigotes tested except one, Sbs PMMr clone 6, were significantly more
resistant to SNAP treatment than their WT counterparts (P  0.05; only data for clone
8 are shown in Table 2). The anomaly for Sbs PMMr clone 6 may be because this clone
had the same PMM susceptibility as the Sbs WT (data not shown). The Sbr WT exhibited
the highest resistance to SNAP treatment at the promastigote stage of the three WT
strains, with an IC50 value that was 9 times higher than that for the other two WT
strains. This may reflect the inherent resistance of this strain to Sb, as Sbr is related to
enhanced resistance to reactive nitrogen species (20). This may explain why the
increase in SNAP resistance for Sbr PMMr clone 9 at the amastigote stage was only 1.3
times higher than that for the Sbr WT, whereas the other PMMr parasites expressed a
much higher differential resistance to SNAP treatment (resistance relative to that of the
WT was 2.1 to 2.6 times higher for the Sbs PMMr strain than for the Sbs WT and 25.3
times higher for the Sbi PMMr strain than for the Sbi WT). 3-Morpholinosydnonimine
(SIN-1) treatment, which induces both NO and superoxide production in macrophages,
did not give a clear differentiation in the fitness of the WT and the PMMr parasites,
based on the IC50 value for SIN-1 exposure (Table 2). The Sbs PMMr and Sbr PMMr
parasites had susceptibility to SIN-1 similar to that of their corresponding WT strains,
whereas Sbi PMMr clone 8 promastigotes were significantly more susceptible to SIN-1
treatment than the Sbi WT (P 0.05). There was a difference in SIN-1 susceptibility
FIG 3 Hydroxy acid production in the different L. donovani strains. (a) General pathway for production
of hydroxy acid derivatives of amino acids in Leishmania. (b) 2-Keto acids and 2-hydroxy acids produced
from isoleucine, arginine, tyrosine, and tryptophan. (c) Differences in hydroxy acid levels in wild-type and
PMM-resistant strains (log2 fold change in metabolite peak intensity). *, P 0.05. Abbreviations: KMVA,
2-keto-3-methylvaleric acid; HMVA, 2-hydroxy-3-methylvaleric acid; HPP, hydroxyphenylpyruvate; HPLA,
hydroxyphenyllactate.
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between the WT strains, with the Sbi WT being the most resistant and the Sbr WT being
the least resistant (Table 1). Overall, the most striking phenotype associated with PMMr
was increased resistance to NO, measured at the IC50 value for SNAP exposure in the
amastigote stage of the parasite. The Sb background of the strains did have an
influence, with the Sbr PMMr strain exhibiting greater resistance to NO.
Genetic variants discriminate PMMs lines from PMMr lines. Only the Sbs and Sbr
strains were used in genotyping studies to determine what influence the two extreme
phenotypes of Sb susceptibility had on PMMr. We screened genome-wide data for
mutations associated with PMM tolerance in the WT and PMMr stages with 2, 4, 8, and
97 M PMM for both the Sbs and Sbr lines, along with 32 and 64 M PMM for the Sbr
line. The Sbs sample had a dose-dependent aneuploidy signature: the copy number of
chromosomes 6, 7, 8, 13, 14, 15, 22, and 32 (eight in total) increased from disomy in the
WT to trisomy in both Sbs PMMr libraries at 8 M PMM (Fig. 5). The Sbr chromosome
copy numbers fell to disomy from trisomy for chromosomes 11 and 14 (at 32 M and
64 M PMM, respectively), as well as from tetrasomy to trisomy for chromosomes 2
FIG 4 Arginine and methionine metabolism in different strains of L. donovani. A pathway map for arginine, proline, methionine, and
cysteine metabolism is shown. The map also includes glutathione and trypanothione biosynthesis. Boxed metabolites were detected in
the metabolic profile of the L. donovani strains by LC-MS. Yellow shading indicates that metabolite identities were confirmed by retention
times matching those obtained with authentic standards; unshaded metabolites were putatively identified by accurate mass only.
Unboxed metabolites were not detected by LC-MS but are presumed to be present. Abbreviations: SAM, S-adenosylmethionine; SAH,
S-adenosylhomocysteine; MTA, 5-methylthioadenosine; OAS, O-acetylserine; GSH, glutathione; GSSG, oxidized glutathione; T(SH)2, re-
duced trypanothione; T(S)2, oxidized trypanothione; P5C, pyrroline-5-carboxylate. Filled arrows represent enzyme reactions known to
occur in Leishmania spp. Dotted arrows show reactions that have not been confirmed. a, the urea cycle is not thought to be complete
in Leishmania; b, nitric oxide synthase activity was detected in L. amazonensis, but the gene has not been identified in any Leishmania
species; c, the oxidation of thiols may occur in situ during cell extract formation and LC-MS.
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and 33 (at 32 M PMM) but rose from disomy to trisomy for chromosomes 1 and 5
(at 32 M PMM). Consequently, there was a marked difference in the somy-level
response for the Sbs and Sbr isolates, highlighting that their adaptation to this drug
may differ.
Transient amplification of the rRNA locus at both kb 1046 to 1053 and kb 1058 to
1065 on chromosome 27 was discovered in both Sbs and Sbr isolates at 2, 4, and 8 M
PMM, but this was absent in the WT line and the lines resistant to 32, 64, and 97 M
PMM (Text S2; Fig. S2 and S3). These amplified regions spanned three (LdBPK_
270030120-140) and four (LdBPK_270030190-220) genes, respectively, where the first
gene of each amplification was the 18S SSU rRNA gene. This increased the local rRNA
gene dosage from 6 (WT strains) to 10 (strains resistant at 2 to 8 M PMM), but this
reverted back to 6 in the strains resistant at 32 to 97 M PMM.
The remaining other genetic changes were a deletion and a heterozygous single
nucleotide polymorphism (SNP). The sole deletion observed was in Sbs PMMr isolates
and was a heterozygous loss of a 1,532-bp region containing an NAD-dependent
epimerase/dehydratase family gene. The sole consistent SNP was a heterozygous one
(G A) at a mitogen-activated protein kinase kinase kinase (MAPKKK) gene
(LdBPK_190007100) at chromosome 19 position 45,638 in the Sbs isolate resistant to
PMM at a low dose (0, 2, 4, 8 M PMM) that became fixed in both Sbs PMMr isolate
clones (97 M). No SNPs were found in the Sbr lines during PMM exposure. No other
PMM-related SNPs, insertions, or episomes that distinguished all PMMs lines from all
PMMr lines in either the Sbs or the Sbr isolates were observed.
DISCUSSION
The results indicated that the induction of PMMr parasites from a single cloned WT
can result in a mixed population of parasites, based on the response of individual Sbs
PMMr subclones and the parental drug-resistant promastigote parasites to SIN-1 or
SNAP treatment. The PMM IC50 values for Nepalese L. donovani WT strains at the start
of this study (for the Sbs PMMr strain, 354 4 M; for the Sbi PMMr strain, 56 22 M;
for the Sbr PMMr strain, 65 2 M) were higher than those quoted for L. aethiopica
clinical isolates from patients with localized cutaneous leishmaniasis (4.44 g/ml or
7.22 M), mucosal cutaneous leishmaniasis (21.8 g/ml or 35.45 M), or diffuse cuta-
neous leishmaniasis (0.20 g/ml or 0.33 M) (21).
One of the most striking phenotypes associated with PMMr parasites compared to
their WT strains was the increased resistance to NO, which was expressed primarily at
the intracellular amastigote stage, and the Sbs PMMr clone had a lower resistance than
the Sbi PMMr and Sbr PMMr parasites. The higher resistance to NO probably reflects
adaptations related to Sbr, which also gives increased resistance to NO (22). A relation-
ship between PMMr and increased resistance to nitrosative stress has been reported in
L. infantum at the intracellular amastigote stage (11), and an Indian L. donovani PMMr
clinical isolate (BHU573) that had PMMr induced using the same protocol showed
increased resistance to SNAP treatment at the promastigote stage but a significantly
lower tolerance at the intracellular amastigote stage (23). It is possible that the clinical
use of PMM as an antibiotic treatment rather than as a first-line antileishmanial
TABLE 2 Susceptibility (IC50) of different L. donovani strains to SIN or SNAP treatment
Strain
Mean  SD IC50 (M)a
SNAP
SIN-1 for
promastigotesPromastigotes Amastigotes
Sbs WT 117  14 111  22 1,242  62
Sbs PMMr clone 8 84  16 285  38* 1,537  31
Sbi WT 239  26 97  5 961  43
Sbi PMMr clone 8 96  8 2,456  342* 306  29*
Sbr WT 57  8 934  41 313  29
Sbr PMMr clone 9 45  1* 1,283  132* 343  37
aThe mean IC50 values are from 3 separate experiments. *, P 0.05, compared to the respective WT.
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treatment may have favored the survival of naturally occurring NO-resistant parasites.
There is a precedent for this type of phenomenon, as genotyping of historical bacterial
strains indicates that methicillin resistance was a result of using methicillin to circum-
vent penicillin resistance in the 1940s. The limited use of methicillin then provided the
selective pressure to drive the nosocomial spread of a variant that was present in the
bacterial population (24). A natural isolate of L. chagasi had a SNAP IC50 value of
48.8 mM, which is approximately 100 times higher than the IC50 obtained in this study,
but the PMM sensitivity of this strain was not determined (25). There are data to
indicate that selection at the amastigote stage can have a more profound effect on
PMM susceptibility in L. donovani. In this study, adaptation to PMMr to 97 M PMM took
26 weeks to develop when using the promastigote stage, and studies using the AG83
L. donovani strain found that it took 3 months to select PMMr using a 10 M stepwise
exposure of promastigotes to PMM up to a maximum of 200 M. In contrast, Hendrickx
et al. (10), who used the same Sbr WT parent used in the present study (BPK275/0cl18),
found that resistance to PMM could be induced within 2 selection cycles if the
intracellular amastigotes were exposed to PMM (mean  standard deviation [SD] IC50,
199.0 8.5 M). This may indicate that the selection of PMMr can occur more rapidly
if drug selection occurs at the amastigote stage. Therefore, it would be prudent to
monitor the resistance of clinical strains to all clinically used antileishmanial drugs to
screen for the evolution of multiple-drug-resistant strains.
The metabolic and lipidomic changes in the three PMMr types of parasites
produced in this study were different and strain specific, suggesting that PMMr was
FIG 5 Different aneuploidy stress responses during PMM selection of the Sbs (BPK282/0cl4) and Sbr
(BPK275/0cl18) lines. The heat map shows the copy number status of the 36 chromosomes with from 0
(wild type) to 2, 4, 8, 32, 64, and 97 M PMM as disomic (blue), trisomic (green), or tetrasomic (ivory). The
color key shows the normalized chromosome read depth and the distribution frequency. Chromosomes
6, 7, 8, 13, 14, 15, 22, and 32 (all at 8 M) shifted from disomy to trisomy in Sbs but not Sbr strains, which
showed an increased somy for chromosomes 1 and 5 (at 32 M), but lower somy for chromosomes 2,
11, and 33 at 32 M and 14 at 64 M.
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mediated by different mechanisms in strains with different genetic backgrounds.
There was no clear marker for the PMMr from an untargeted analysis of metabolites
present or a targeted analysis determining the metabolites associated with resis-
tance to oxidative stress in Leishmania, i.e., glutathione and proline. Surprisingly
fewer metabolic/lipidomic changes occurred for PMMr strains than for MILr strains
in which resistance was induced using the same parental clones (19). This may be
related to the mode of action or these drugs, indicating that PMM has fewer targets
in the parasite than MIL. This finding is similar to the results of Berg et al. (17) using
an L. donovani strain isolated in Ethiopia (MHOM/ET/67/HU3), where PMMr resulted
in 14 metabolic changes compared to the metabolism of the WT, whereas MILr
induced 20 changes. A recent study found that PMMr was associated with increased
glycolytic activity to form products that can scavenge hydrogen peroxide (26).
However, the results from this study did not show any major changes in TCA cycle
metabolites. PMMr was associated with changes in 2-hydroxy acid production from
certain amino acids. In Leishmania, the transamination of amino acids to their
corresponding 2-keto acids involves a broad-specificity aminotransferase that can
use aromatic amino acids and a branched-chain amino acid, aminotransferase
(BCAT), with a specificity for leucine, isoleucine, and valine (27). The 2-hydroxy-acid
dehydrogenase(s) responsible for the reduction of the 2-keto acids to form lactates
has not been identified. In lactic acid bacteria (28) and protozoa, such as Trichomo-
nas vaginalis (29), these reactions are catalyzed by the canonical NAD-dependent
hydroxy acid dehydrogenase lactate dehydrogenase (LDH), an enzyme with broad
substrate specificity (30). Leishmania species do not encode LDH, but genes for
malate dehydrogenases (MDH) and a putative D-lactate dehydrogenase (D-LDH) are
present. Recently, the upregulation of D-LDH and BCAT mRNA was linked to PMMr
in L. donovani by transcriptome sequencing (RNA-seq) analysis of WT and PMMr
strains (15). Overexpression of the putative D-LDH in L. donovani, L. major, and L.
infantum also increased PMM resistance, and there was cross-resistance with other
aminoglycosidic antibiotics. Similar results were observed following the overexpres-
sion of BCAT, although there was no additive effect when BCAT and D-LDH were
coexpressed in the same line. The authors proposed that the enzymatic modifica-
tion of amino or hydroxyl groups on the antibiotics could contribute to the
resistance mechanisms of BCAT and D-LDH (15). In the present study, the levels of
2-keto-3-methylvaleric acid (KMVA), the 2-keto acid derivative of isoleucine, indi-
cated increased BCAT activity in the Sbi PMMr strain compared to that in the
corresponding WT. The high levels of hydroxyphenyl lactic acid and arginic acid in
the PMMr strains derived from Sbs and Sbr strains must result from increased
2-hydroxy acid dehydrogenase activity. These new metabolomic data support a role
for increased BCAT and/or D-LDH activity in PMMr in L. donovani, based on RNA-seq
analysis.
Aneuploidy is hypothesized to represent an early adaptive response to drugs,
but this assertion is complicated by its intrinsic dynamic nature within and across
Leishmania species and life cycle stages to modulate the expression of the majority
of genes (31, 32). Here, the higher copy number of seven chromosomes for the Sbs
isolates associated with 8 M PMM contrasted with the jump in somy for different
chromosomes in the Sbr isolates (chromosomes 1 and 5), along with the fall in somy
for chromosomes 2, 11, and 33 at 32 M PMM and also for chromosome 14 at 64
M. This result shows again that the genetic background of the strains used in the
selection experiment may influence the outcome of the consecutive molecular
adaptations. This genetic diversity may also explain why PMM selection resulted in
the emergence of the PMMr parent and subclone with PMM IC50 values different
from those for the Sbs WT. A study comparing the efficacy of dosing L. donovani-
infected patients in Sudan with PMM at 15 mg/kg of body weight for 28 days with
that of dosing with PMM at 20 mg/kg for 21 days showed that peak PMM plasma
levels occurred approximately 1 to 2 h after dosing and that both dosing regimens
gave drug levels that were much lower than 13 g/ml (mean values on day 1,
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7.8 4.9 g/ml [i.e., 12.6 M] with dosing at 20 mg/kg and 5.6 4.2 g/ml [i.e.,
9.1 M] with dosing at 15 mg/kg). At 6 months of follow-up, both of these regimens
were associated with an 80 to 81% cure rate, indicating that some patients still
harbored parasites (33). Based on our data, the remaining parasites would have
been exposed to sufficient drug (i.e., 8 M) to induce the change in gene somy
required for PMMr.
PMM is an aminoglycoside affecting ribosome function and membrane fluidity
(23), and studies have shown that PMM targets the decoding A site of the ribosome
SSU, with mutations at positions 1408 and 1491 determining sensitivity to PMM
(13). In this study, we found a transient rRNA locus amplification at 2 to 8 M PMM
in both Sbs and Sbr strains, indicating that at low doses, the 18S SSU rRNA gene
transcription rate probably increases, highlighting an alternative PMM tolerance
mechanism. The only consistent SNP in PMMr parasites was a heterozygous one
(G A) at an MAPKKK gene in the Sbs line. MAPKKK proteins activate mitogen-
activated protein kinase kinase proteins through the phosphorylation of serine and
serine/threonine residues in the T loop. A study in Larix olgensis found that
MAPKKKs were induced by NO at the transcriptional level, and it is known that NO
upregulates mitogen-activated protein kinases (34). So, perhaps it is no coincidence
that in this study PMMr in L. donovani was associated with increased resistance to
NO induced by SNAP treatment. This is important to ascertain, as it may be possible
to produce an inhibitor or provide a supplement that could reverse PMM resistance
and extend the clinical life of the drug against L. donovani. In a previous study
based on Cos-Seq, the copy number of the LinJ.06.1010 gene, with its leucine-rich
repeat domain, was found to be responsible for the resistance to PMM (14), but this
was not verified by Rastrojo et al. (15), while in the present study, we did not find
a local copy number variation but did find an increase in the copy number of
chromosome 6. These different results obtained with different strains might again
highlight the influence of the genetic background on the outcome of molecular
adaptations developed during resistance selection. Last but not least, our work is
consistent with the lack of PMM-MIL cross-resistance (35), underlining the potential
use of this pair as a combination treatment.
In summary, this study showed that resistance to PMM is present in an L.
donovani isolate from Nepal in the absence of PMM drug pressure. It was relatively
easy to induce resistance in L. donovani, and the subclones produced from the
parental PMMr line could express different levels of PMM resistance. PMMr was
associated with enhanced resistance to NO, the mechanisms that control PMMr
varied between lines, and the Sb resistance profile of the parasite, together with its
genetic background, had an impact on the outcome of selection. The PMMr strains
had significantly higher levels of either the keto acid KMVA or 2-hydroxy acids
(arginic acid and HPLA), which may indicate the upregulation of BCAT or D-lactate
dehydrogenase, activities recently linked to PMMr. The challenge now is to expand
this study to a larger number of field isolates to determine the predominant
phenotype present in areas of endemicity.
MATERIALS AND METHODS
Reagents. Pure crystalline PMM (paromomycin sulfate USP) was supplied from Gland Pharma, India.
Resazurin, SNAP, Giemsa stain, and lipopolysaccharide were purchased from Sigma-Aldrich (Gillingham,
UK). HOMEM medium, RPMI 1640, phosphate-buffered saline (PBS), pH 7.4, penicillin-streptomycin,
glycine, and fetal calf serum were obtained from Invitrogen, Paisley, UK. SDM medium was custom made
by Gibco, Paisley, UK. S-Nitroso-N-acetyl-D,L-penicillamine (SNAP) and 3-morpholinosydnonimine (SIN-1)
were purchased from Enzo Life Sciences, Exeter, UK. All other reagents were analytical grade.
Animals and parasites. Age-matched inbred BALB/c female mice (weight, 20 to 25 g) were used in
studies at Strathclyde University. Animal studies were carried out with local ethical approval and had UK
Home Office approval. L. donovani cloned strains with different Sb susceptibility backgrounds were
derived from isolates obtained from VL patients at the B. P. Koirala Institute of Health Sciences, Dharan,
Nepal: MHOM/NP/02/BPK282/0cl4 (Sbs). MHOM/NP/02/BPK087/0cl11 (Sb intermediate [Sbi]), and MHOM/
NP/02/BPK275/0cl18 (Sbr) (16).
Selection of PMMr clones. L. donovani strains were adapted to grow in a stepwise manner in
increasing concentrations of PMM (2, 4, 8, 16, 32, 64, 97 M) until all lines grew at rates similar to
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the rate for the wild-type (WT) parasites in HOMEM medium supplemented with 20% (vol/vol) fetal
calf serum (complete HOMEM). The highest concentration of PMM used was 97 M, as the parasites
did not grow well in the presence of higher drug concentrations. Parasites selected to grow as well
as the WT in 97 M PMM were termed PMM resistant (PMMr), and their specific designation depends
on the WT used; i.e., the Sbs PMMr parental line was derived from BPK282/0cl4, the Sbi PMMr parental
line was derived from BPK087/0cl11, and the Sbr PMMr parental line was derived from BPK275/0cl18.
Clones from the parental drug-resistant line were isolated, expanded in Locke medium on top of
Tobie’s agar base, and then grown in complete HOMEM. A stock solution of aqueous PMM (3 mg/ml,
freshly prepared every 3 months) was stored at 20°C and used to prepare drug selection medium.
Clones were produced from the parental PMMr lines using the microdrop technique (10) and
designated with a number.
Genetic characterization of Sbs PMMr and Sbr PMMr strains. Cell harvesting, lysis, genomic DNA
isolation, and genome sequencing were completed as outlined previously (19). Genomic DNA was
sequenced on an Illumina HiSeq 2000 platform, with the median sequence coverage being
47.4 17.8 reads per site averaged across 15 sequence libraries (see Table S2 in the supplemental
material posted at https://doi.org/10.15129/88f47c26-ff93-4a7c-8c17-d323aa24052e). Following
screening for contamination, the DNA reads for each library with insert sizes of less than 1,000 bases were
mapped to a new L. donovani LdBPK282 reference genome using the Smalt program with exhaustive
alignments (v0.7.4; https://sourceforge.net/projects/smalt/) (35). All nonmapping and PCR duplicate
reads were removed. Sites with low-quality scores, in repetitive regions, with poor mapping scores, in
low-complexity regions, with significant forward-reverse strand amplification bias, or with low read
coverage were excluded. Chromosome copy number variation and scans for large copy number
variations and episomes were performed based on the per cell read depth, to reflect gene dosage, as
outlined previously (36). Changes in chromosome copy numbers were detected by comparing the
distributions of coverage levels across all sites for each chromosome using t tests, as outlined elsewhere
(37). SNPs, small insertions, and deletions were called using the population-based Unified Genotyper
method in the Genome Analysis Toolkit (v3.4) with the parameters described previously (37).
Phenotyping of promastigotes. The effects of amphotericin B (AMB), PMM, SIN-1, and SNAP on
the growth of the promastigotes were determined using a colorimetry-based assay according to the
method described by Shaw et al. (19). Parasites (5 105 parasites/100 l, n 6/treatment) were
exposed at time zero to AMB (1 M) or various concentrations of PMM, SIN-1, or SNAP (n 6/
treatment) for 1 h (SIN-1 studies) or 72 h (AMB, PMM, or SNAP studies) at 27°C. After 1 h of exposure,
the SIN-1 solution was removed, fresh medium was added, and the cells were incubated for a further
71 h. In some studies, proline (200 mM) was added to the medium with or without PMM solution, as
this proline concentration was used in previous studies investigating the role of proline in drug
resistance in L. donovani (17). Parasites were exposed to AMB to show whether resistance to PMM
was drug specific. Resazurin solution (20 l/sample, 0.0125% [wt/vol] PBS, pH 7.4) was added to the
samples for the last 18 h of culture, and then the absorbance of samples at 550 to 590 nm was
determined using Softmax Pro (v2.0) software. The effect of drug treatment on cell viability was
determined by calculating the mean suppression compared to the relevant mean control value, and
this was used to determine the IC50 for a particular drug/compound using Grafit (v5) software.
Metabolic and lipidomic characterization studies. Extraction of the lipids or metabolites was
carried out using 4 107 L. donovani promastigotes/strain obtained on day 4 of culture using the
methods described by Shaw et al. (19). Specific metabolites were identified using IDEOM, and 4 standard
mixes were used in assays, whereas lipids were identified using Xcalibur software (v2.2) and an in-house
Excel macro. PCA and OPLS-DA plots were produced using published methods (38) and SIMCA software
(v14.1). The experiments were repeated three times, but data from one single representative experiment
performed using all samples in one run are shown.
Phenotyping of intracellular amastigotes. The method for the phenotyping of intracellular amas-
tigotes described by Carter et al. (22) was followed. Briefly, peritoneal macrophages (0.5 105/sample,
n 5/treatment) from BALB/c female mice were infected with L. donovani promastigotes at a host/
parasite ratio of 20:1 for 24 h. Infected cells were incubated for 72 h with medium alone (controls), SNAP
(10 to 160 g/ml), or IFN- and LPS (IFN-, 50 or 100 U/ml; LPS, 50 or 100 ng/ml). The percentage of
infected macrophages and the mean number of parasites per host cell were determined from 200
randomly selected infected cells; infectivity was determined by multiplying both parameters. The effect
of treatment on parasite survival was determined as the mean percent suppression compared to the
relevant mean control value. Experiments were repeated a minimum of three times.
Statistical analysis of data. The effect of drug treatment on cell proliferation in in vitro drug studies
was analyzed using a Mann-Whitney U test for comparing two treatments or a Kruskal-Wallis test
followed by Dunn’s ad hoc test for determination of statistically significant differences between three or
more treatments (Statview [v5.0.1] software package). Results were considered significant at a P value of
0.05.
Data availability. Supplemental data and data underpinning this publication are available from the
University of Strathclyde KnowledgeBase at https://doi.org/10.15129/88f47c26-ff93-4a7c-8c17-d323aa24052e.
Raw sequence reads are available from the European Nucleotide Archive (ENA) via accession number
ERP115194. All data used in this study have been deposited under BioProject accession number
PRJEB32497 as Sequence Read Archive accession numbers ERS197378, ERS161532, ERS160178,
ERS160177, ERS160176, ERS197372, ERS340112, ERS340111, ERS340110, ERS197378, ERS161532,
ERS160178, ERS160177, ERS160176, and ERS197372 (see also Table S4 posted at https://doi.org/10
.15129/88f47c26-ff93-4a7c-8c17-d323aa24052e).
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